AW
CLDX icon

Avion Wealth’s Celldex Therapeutics CLDX Stock Holding History

Avion Wealth’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
24
– – ﹤0.01% 1289
2025
Q4 		$0 Hold
24
– – ﹤0.01% 1284
2025
Q3 		$0 Hold
24
– – ﹤0.01% 1251
2025
Q2 		$0 Buy
+24
New +$467 ﹤0.01% 1235

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Avion Wealth's CLDX Position: Q1 2026 in Review

Avion Wealth held its Celldex Therapeutics (CLDX) position steady in Q1 2026 at 24 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #1289.

Avion Wealth first reported a position in CLDX in Q2 2025 and has held it in 4 quarters since. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Avion Wealth held 24 shares of Celldex Therapeutics worth $0 as of Q1 2026.
  • Avion Wealth left its Celldex Therapeutics share count unchanged in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Avion Wealth's portfolio in Q1 2026, its #1289 holding.
  • Avion Wealth first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Avion Wealth's 13F filing for Q1 2026, filed 1 May 2026.